Background: To determine dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and pharmacokinetics (PK) of oxaliplatin administered as hepatic arterial infusion.
Introduction

Patients and methods
Colorectal cancer (CRC) is diagnosed in more than 130,000 patients in the year 2000 in the US and hepatic metastases are present at diagnosis or during disease progression in two thirds of them [1] . Treatment options for patients with metastases confined to the liver include surgery [2] [3] [4] , systemic chemotherapy [5] and hepatic arterial infusion (HAI) mostly with antineoplastic agents characterized by high systemic clearance values [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . However, it is still unclear which patients may benefit most from HAI [20] . Specifically, data on the feasibility and efficacy of HAI using new substances like oxaliplatin, which proved to be effective when applied systemically to patients with advanced CRC [21] [22] [23] [24] [25] , are not available yet. The current phase I trial was performed to determine the dose-limiting toxicity, the maximum tolerated dose, and the pharmacokinetics of oxaliplatin administered as hepatic arterial infusion in combination with folinic acid and 5-fluorouracil (5-FU) to patients with hepatic metastases of colorectal cancer.
Patients
Consecutive patients at ages 18 or older with surgically removed colorectal cancer and metastatic disease confined to the liver with or without prior systemic or regional chemotherapy who were admitted to the university hospital GroBhadern, Munich, between November 1998 and March 2000 were eligible for the study. Patients with metastases outside the liver or prior therapy with oxaliplatin were excluded from the study. Further exclusion criteria comprized coronary heart disease; heart failure, cardiomyopathy, severe arterial hypertension, abnormal liver function tests (total bihrubin >4.0 mg/dl), impaired renal function (serum creatinine > 2.0 mg/dl), impaired hematopoiesis (WBC count < 1500 G/l, platelet count < 100 G/l), severe infections, or pregnancy.
Chemotherapy
All patients received the chemotherapy via a radiologically implanted chamber device as long-term venous access Combination chemotherapy comprized folinic acid 200 mg/m 2 as a one-hour infusion and 5-FU 600 mg/m 2 as a two-hour infusion, respectively, for five consecutive days and oxaliplatin as a four-hour infusion on days two and four. 
Study parameters
Hematologic and non-hematologic toxicity was assessed according to NCI Common Toxicity Criteria. Response to therapy was assessed according to WHO criteria by sonographic imaging [26] .
Pharmacokinetic analyses
Plasma levels of ultrafiltrable platin and renal excretion of platin were determined by atomic absorption spectrometry as descnbed recently [27] . During the first and second cycle of chemotherapy, 5 ml blood samples were drawn into NH 4 -heparinized tubes hourly during the infusion, every 20 minutes during 2 hours thereafter, every hour until 6 hours after the end of infusion, and on 3 time points on the following day. The plasma was separated immediately and an aliquot was ultrafiltrated by Amicon filters NMWL 10,000 (Amicon, USA). The ultrafiltrate and total plasma samples were stored immediately at -20 "C for a maximum of two weeks. The total urine excreted during the infusion and 24 hours thereafter was collected in fractions and stored immediately at -20 °C for a maximum of two weeks. The determination of the platin concentrations of the respective specimens was performed by flameless atomic absorption spectrometry using a GBC 904 AA (Maassen, Germany) as described previously [27] . The method was linear between platin concentrations of 30 ng/ml (limit of detection) and 1000 ng/ml. Both within-day and between-day variations were less than 10% for plasma and urine samples. Proteinbound platin was calculated as the difference between total and free platin for each plasma sample Separately performed analyses of pharmacokinetic results for each treatment cycle were based on theTOPFIT computer program providing an optimized adaptation of coefficients of variation between the observed and calculated respective data [28] . A three-compartmentmodel was used for fitting the data which is demonstrated in Figure 1 . The substance is distributed from dosing compartment to the central compart and vive versa. From the latter it is distributed both to the deep compartment and vice versa and to the elimination comparment which corresponds to the urine.
Study conduct
Prior to therapy all patients gave their informed consent for participation in the current evaluation after having been advised about the purpose and investigational nature of the study as well as of potential risks. The study design adhered to the declaration of Helsinki and was approved by the ethics committees of the participating institutions prior to its initiation.
Results
Patients
Twenty-one patients have been entered into the study all of whom are fully evaluable. Fourteen patients were male, the median age was 61 years (range 34-76 years). The median interval from diagnosis to study entry amounted to 11 months (range 1-109 months) and the median number of prior chemotherapeutic regimens 
Toxicity
The DLT has been observed at dose level 6, i.e., at 150 mg/m 2 /cycle (Table 1) . Accordingly, the MTD was determined to be 125 mg/m 2 /cycle. DLT consisted of obliteration of the hepatic artery in two patients. This was diagnosed in one asymptomatic patient two weeks after completion of the second cycle of chemotherapy and in the other patient upon severe upper abdominal pain during the first infusion of oxaliplatin. The third patient with DLT suffered from acute pancreatitis which occured on day 2 of the first cycle of chemotherapy. This was due to a dislocation of the catheter tip into the gastroduodenal artery. In addition, in the first above mentioned patient as well as in another patient leucopenia NCI-CTC grade 3 was documented. Overall, toxicity mainly consisted of nausea/vomiting (16 of 21 patients), anemia (16 of 21), upper abdominal pain (15 of 21), sensory neuropathy (10 of 21), diarrhea (9 of 21), and thrombocytopenia (9 of 21). Toxicity rated severe according to NCI-CTC grade 3-4 included leucopenia (4 of 21), thrombocytopenia (2 of 21), hyperbilirubinemia (2 of 21), pain (2 of 21), and diarrhea (1 of 21).
Pharmacokinetics
Pharmacokinetic analyses have been performed in three patients at each dose level during one or two cycles (total, 18 patients and 33 cycles). The courses of ultra- filtrable platin concentrations and of cumulative renal elimination of the drug are shown in Figure 2 . The slow increase during the infusions and the bi-phasic decay thereafter of plasma concentrations as well as the corresponding cumulative renal elimination of the drug are similar to the figures observed during intravenous infusion of oxaliplatin. Fitting the measurements of ultrafiltrable platin in plasma and urine to the above described three compartment model results in the pharmacokinetic data listed in 
Antitumor efficacy
Eighteen patients were evaluable for response and nineteen patients were evaluable for time to disease progression. Four of eighteen patients (24%) achieved a complete remission and six achieved a partial remission (35%; overall response rate, 59%). Four patients had stable disease and four had progressive disease. The median time to tumor progression estimated according to Kaplan and Meier has not been reached. At the median follow-up of 6.7 months the estimated level of the Kaplan-Meier plot is at 67%.
Discussion
Hepatic arterial infusion is a valuable therapeutic option for patients with hepatic metastases from colorectal cancers both not eligible for surgery as well as following complete resection and may be more effective than systemic chemotherapy alone [6] [7] [8] [9] [10] . While the addition of oxaliplatin and irinotecan to standard chemotherapy combination regimens of folinic acid and 5-FU has been shown to improve the antitumor efficacy when administered systemically [5, 21-25, 29, 30] , the role of these new agents during HAI has not yet been determined. Hence, they may increase the response rate and long-term results also during this treatment modality and additional analyses are needed to establish their optimal dosing schedule and to substantiate the therapeutic potential. The current study evaluated the side effects and pharmacokinetics of oxaliplatin applied as HAI in combination with folinic acid and 5-FU. The toxicity was similar to the one observed following the systemic administra-tion of the same drugs with the exception of upper abdominal pain. This occurred in 15 of 21 patients and is considered the result of higher local drug concentrations as compared to intravenous therapy. Accordingly, this complication has been observed regularly during various combination of drugs applied as HAI [6, 31] . However, as in the previous studies these symptoms mostly were not severe (current study: NCI-CTC grade 1-2, 13 patients; NCI-CTC grade 3-4, 2 patients) and were managable by the administration of analgesics. The other toxicities encountered are similar to the figures during the systemic application of the same combination with regard to both frequency and severety. Especially, mild sensory neuropathy, which is a specific side effect of oxaliplatin, occured in 10 of 21 patients while severe neuropathy was not observed. This corresponds to the 45% incidence observed during the intravenous administration of oxaliplatin in combination with folinic acid and 5-FU [21] . However, since this complication may result mainly from cumulative doses of the drug, additional observations of patients receiving the MTD for a longer follow-up will be needed to more accurately estimate the incidence of this side effect. Other freuquently observed toxicities included nausea/vomiting and hematotoxicity which both are well characterized also during systemic application of oxaliplatin [21, 22, 24, 25] . Overall, severe toxicity according to NCI-CTC grade 3-4 was observed in four patients with leucopenia, in two with thrombocytopenia, in two with hyperbilirubinemia, in two with pain, and in one with diarrhea. Most of these side effects occured in intensively pretreated patients and may in part be due to preexisting decreased hematopoietic reserve and progression of the disease, respectively. Overall, the combination of oxaliplatin with folinic acid and 5-FU was well tolerated and can be savely administered, especially to chemonaive patients in which the side effects may be even less pronounced.
The pharmacokinetic profile of oxaliplatin during HAI as assessed in the current study differs in part from its characteristics during intravenous application [27] . Hence, with regard to the values for the terminal halflife (17.8 ± 9.3 hours versus 27.3 ± 10.6 hours; student's /-test, P = 0.001) and for the AUC (17.76 ± 7.80 ug • h/ml versus 20.17 ± 6.97 ug • h/ml; P -0.25) it may indicate a slightly reduced systemic availability of the drug during HAI as compared to its intravenous application and may thus provide an additional basis for the concept of higher drug availability at the target organ during intraarterial therapy. As has been expected, once the drug had entered the systemic circulation its pharmacokinetics were comparable for both modalities of application (renal clearance 135 ± 55 ml/min versus 121 ± 56 ml/min, P -0.37; renal elimination 49% ± 14% versus 54% ± 20%, P = 0.26). The AUC increased linearly from doses of 25 mg/m 2 to 125 mg/m 2 and further proof the safety of the current regimen. The lack of a further increase of the AUC at a dose of 150 mg/m 2 probably is related to a higher clearance and not nessessarily indicates the beginning of non-linear pharmacokinetics at this dose level.
A clinical benefit as assessed by either complete or partial response or stable diseasse has been achieved in 14 of 18 evaluable patients (78%). However, due to the relatively short follow-up period of 6.7 months the median time to tumor progression has not been reached and currently amounts to 67%. Although not being the primary endpoint of the current study these efficacy data in this small cohort of 21 patients suggest that this regimen might have a future place in the management of patients with isolated hepatic metastases from colorectal cancer and warrants its evaluation in phase II studies.
